board. Shortly thereafter, Walgreens ended its relationship with Theranos and closed its in-store blood collection centers. The U.S. Food and Drug Administration (FDA) also ordered the company to cease use of its Capillary Tube Nanotainer device, one of its core inventions. In 2017, the State of Arizona filed suit against Theranos, alleging that the company had sold 1.5 million blood tests to Arizonans while concealing or misrepresenting important facts about those tests. In April 2017, the company settled the lawsuit by agreeing to refund the cost of the tests to consumers, and to pay $225,000 in civil fines and attorney fees, for a total of $4.65 million. Other reported ongoing actions include an unspecified investigation by the U.S. Federal Bureau of Investigation (FBI) and two class action fraud lawsuits. Holmes denied any wrongdoing. On May 16, 2017, approximately 99 percent of Theranos shareholders reached an agreement with the company to dismiss all current and potential litigation in exchange for shares of preferred stock. Holmes released a portion of her equity to offset any dilution of stock value to non-participating shareholders. In March 2018, the SEC charged Holmes and Theranos's former president, Ramesh Balwani, with fraud by taking more than $700 million from investors while advertising a false product. On March 14, 2018, Holmes settled an SEC lawsuit. The charges of fraud included the company's false claim that its technology was being used by the U.S. Department of Defense in combat situations. The company also lied when it claimed to have a $100 million revenue stream in 2014. That year, the company only made $100,000. The terms of Holmes's settlement included surrendering voting control of Theranos, returning 18.9 million shares to the company, a ban on holding an officer or director position in a public company for 10 years, and a $500,000 fine. At its height in 2015, Theranos had more than 800 employees. It dismissed 340 people in October 2016 and an additional 155 in January 2017. In April 2018, Theranos filed a WARN Act notice with the State of California, announcing its plans to permanently lay off 105 employees, leaving it with fewer than two dozen employees. Most of the remaining employees were laid off in August 2018. On September 5, 2018, the company announced that it had begun the process of formally dissolving, with its remaining cash and assets to be distributed to its creditors. U.S. v. Holmes,